Skip to main content

Research News

academics

 

Clinical research courses

  • Oral insulin drops offer relief for diabetes patients

    Pre-clinical tests showed that insulin with the peptide effectively reaches the bloodstream whereas without the peptide, insulin remains stuck in the inside lining of the mouth.
  • Researchers develops novel antibody treatment for Kidney Cancer
    Antibody therapies called bispecific T cell engagers have emerged as effective treatments for some blood cancers but have been more difficult to develop for solid tumors. While clinically successful, first-generation BTEs suffer a short half-life.
  • U.S. Drug-related infant deaths more than doubled in five years
    A new study by Florida Atlantic Universitys Schmidt College of Medicine has uncovered a disturbing trend in drug-related infant deaths in the United States from 2018 to 2022.
  • Scientists discover a novel modulator of human regulatory T cells

    The T cells in our blood fight against cancer, viruses and bacteria. Specific regulatory T cells are required to control faulty immune responses, and disruption in their function may lead to autoimmune diseases or cancer.

  • Engineered DNA 'warhead' targets a common cancer mutation
    Tumour protein P53 (TP53) plays an important role in suppressing the growth of tumours. Mutations in the gene for TP53 can have a disastrous effect, hampering the body's ability to fight tumours and even encouraging their growth. Because these are the most common mutations in cancers, TP53 has long been an interesting therapeutic target. However, efforts to destroy the mutant protein have been hampered by the difficulty of finding a way to bind to it.
  • Heart healthy behaviors may help reverse rapid cell aging

    The benefit of better heart health may be associated with the positive impact of heart healthy lifestyle factors on biological aging (the age of the body and its cells), according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

  • New study discovers tiny target on RNA to short-circuit inflammation
    This peptide originates from within a long non-coding RNA called LOUP. According to the researchers, the human genome encodes over 20,000 lncRNAs, making it the largest group of genes produced from the genome. But despite this abundance, scientists know little about why lncRNAs exist or what they do
  • Scripps Research scientists uncover new molecular drivers of Alzheimer’s

    According to the US Centers for Disease Control and Prevention, at least 5.8 million Americans are currently living with Alzheimer’s disease, which is the most common form of dementia. There is no cure for Alzheimer’s, in part because scientists do not yet have a full understanding of what causes the disease. But a new study from Scripps Research is shedding light on the molecular drivers that could contribute to Alzheimer’s progression.

  • New advances in cancer viral immunotherapy

    Vaccinia viruses are therapeutic tools with different biomedical applications depending on the susceptibility characteristics. For example, the strain called MVA (modified vaccinia Ankara), which is unable to replicate in mammalian cells, triggers a potent immune system response and is used to develop vaccines against COVID-19 or AIDS. In contrast, other strains such as Western Reserve (WR) or Copenhagen (Cop), which replicate efficiently in tumour cells, are used to develop cancer treatments.

  • A Trial HIV Vaccine Triggered Elusive and Essential Antibodies in Humans

    An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

    The finding, reported May 17 in the journal Cell, not only provides proof that a vaccine can elicit these antibodies to fight diverse strains of HIV, but that it can also initiate the process within weeks, setting in motion an essential immune response.

Subscribe to Research News